New 4-amino-2-azabicyclo[3.2.2]nonane derivatives and their antiprotozoal potencies (Publications)
East African sleeping sickness, Trypanosoma b. rhodesiense, and a protozoan parasite which causes Malaria tropica, Plasmodium falciparum K-1, a strain which is resistant to chloroquine and pyrimethamine
Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles (Publications)
activity against chloroquine-sensitive (NF54) and multi-drug resistant (K1) strains of the human malaria parasite Plasmodium falciparum. Compounds were also screened for their cytotoxicity towards a mammalian
New 4-amino-2-azabicyclo[3.2.2]nonane derivatives and their antiprotozoal potencies (Publications)
East African sleeping sickness, Trypanosoma b. rhodesiense, and a protozoan parasite which causes Malaria tropica, Plasmodium falciparum K-1, a strain which is resistant to chloroquine and pyrimethamine
Incorporation of an intramolecular hydrogen bonding motif in the side chain of antimalarial benzimidazoles (Publications)
activity against chloroquine-sensitive (NF54) and multi-drug resistant (K1) strains of the human malaria parasite Plasmodium falciparum. Compounds were also screened for their cytotoxicity towards a mammalian
Comparative ex vivo activity of novel endoperoxides in multidrug-resistant <em>Plasmodium falciparum</em> and <em>P. vivax</em> (Publications)
potent compounds for the treatment of malaria. In Papua Indonesia, where multidrug resistance has been documented against both P. falciparum and P. vivax malaria, comparative ex vivo antimalarial activity
The potential of artemether for the control of schistosomiasis (Publications)
Schistosomiasis continues to rank - following malaria - at the second position of the world's parasitic diseases in terms of the extent of endemic areas and the number of infected people. There is yet [...] Interestingly, derivatives of artemisinin, which are already effectively used in the treatment of malaria, also exhibit antischistosomal properties. Significant advances have been made with artemether, the
Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites (Publications)
schistosomiasis, a chronic and debilitating parasitic disease of the tropics, is ranked second after malaria in terms of public health importance. At present, there is no vaccine available, and chemotherapy [...] with artemether, the methyl ether of dihydroartemisinin, already widely used for the treatment of malaria. The present article reviews the literature that led to the development of artemether for chemop
Activation of TCR Vδ1+ and Vδ1-Vδ2- γδ T cells upon controlled infection with <em>Plasmodium falciparum</em> in Tanzanian volunteers (Publications)
immune response to malaria remains incomplete. Clinical trials using whole-sporozoite-based vaccination approaches such as the Sanaria PfSPZ Vaccine, followed by controlled human malaria infection (CHMI)
Parasite-host dynamics throughout antimalarial drug development stages complicate the translation of parasite clearance (Publications)
Ensuring continued success against malaria depends on a pipeline of new antimalarials. Antimalarial drug development utilizes pre-clinical murine and experimental human malaria infection studies to evaluate
New <em>in vitro</em> interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations (Publications)
The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require [...] will significantly improve and streamline the economic development of new drug combinations for malaria and potentially also in other therapeutic areas.